Life sciences platform enhanced to make cognitive assessments
easier and more precise
BOSTON, July 24,
2024 /PRNewswire/ -- Linus Health, a digital
health company focused on enabling early detection of cognitive
impairment, Alzheimer's and other dementias, will be presenting
more than a dozen sessions and posters at the Alzheimer's
Association International Conference (AAIC) taking place
July 28-Aug. 1 in Philadelphia, and virtually.
The Linus team will be at Booth #830 to discuss its cutting-edge
Alzheimer's research as well as share updates and provide hands-on
demonstrations of new assessments added to the company's brain
health platform. Foremost among these significant enhancements
are:
- A patent-pending amyloid predictor that estimates the
likelihood of A𝛽 PET positive status based on a machine-learning
model using various multi-modal drawing, voice and speech, and
stylus measures obtained during Digital Clock & Recall
assessment.
- A pre-screening platform that reduces the burden on
participants and provides a rapid, low-cost solution for more
randomized participant selection using a two-phased approach to
enhance recruitment with short eligibility assessments that
efficiently eliminate ineligible participants. Its remote
capabilities broaden study populations to ensure the correct
balance of participants and diversity for each study.
- An electronic Person Specific Outcome Measure (ePSOM™) tool to
capture and monitor patient-reported outcomes in studies and enable
true personalized recommendations and interventions.
The research topics that Linus thought leaders will present at
AAIC range from using artificial intelligence (AI) in digital
cognitive assessment tools to the integration of a digital
cognitive assessment tool in a primary care setting.
"Clinicians and researchers are on the cusp of breakthroughs in
the detection and treatment of dementia," said Linus Health CEO and
Co-Founder David Bates, PhD.
"Conferences like AAIC are prime opportunities to share research
and insights fueling those advancements, including Linus Health's
groundbreaking research into dementia screening and the importance
of early intervention for mild cognitive impairment."
The pre-conference sessions are:
- "The Electronic Person-Specific Outcome Measure (ePSOM) in the
US population: What Matters to Individuals the Most About Their
Brain Health," by Stina Saunders,
PhD, Personalized Medicine Lead, Linus Health. Saturday, July 27.
- "Digital Cognitive Screening and ML-Enabled Random Forest
Modeling for the Detection of Cognitive Impairment," by
Ali Jannati, MD, PhD, Director of
Cognitive Science-Medical Affairs, Linus Health. Saturday, July 27.
The oral presentations are:
- "Early Identification of Alzheimer's Disease with a Machine
Learning-Enabled Digital Cognitive Assessment: Concurrent Detection
of Cognitive Impairment and Amyloid-Beta PET Status," by Jannati.
Part of Featured Research Session: 2-21-FRS-C, 2:00 to 3:30 p.m., Monday,
July 29. Session #93435.
- "The Electronic Person-Specific Outcome Measure (ePSOM) in the
U.S. Population: What Matters to Individuals the Most About Their
Brain Health," by Saunders. Part of Lightning Presentation Round
1-5-LPR, 8:00 to 8:45 a.m.,
Sunday, July 28.
The poster presentations include:
- "Integration of a Digital Cognitive Assessment Tool in a
Primary Care Setting," by Jannati. Part of Dementia Care Research
and Psychosocial Factors: Dementia Care Research, 7:30 a.m. to 4:15 p.m., Wednesday, July 31. Poster #89522
- "Validation of Clinical Decision Support Recommendations of a
Digital Cognitive Assessment by Expert Cognitive Neurologists," by
Jannati. Part of Biomarkers, 7:30 a.m. to
4:15 p.m., Sunday, July 28.
Poster #92040
- "Digital Cognitive Screening and ML-Enabled Random Forest
Modeling for the Detection of Cognitive Impairment," by Jannati.
Part of Biomarkers, 7:30 a.m. to 4:15
p.m., Wednesday, July 31.
Poster #89936
- "DCTclock™ Metrics Differentiate Between Amnestic and Vascular
Mild Cognitive Impairment," by Brendan
Haas, PhD, Senior Data Scientist, Linus Health. Part of Clinical Manifestations:
Neuropsychiatry and Behavioral Neurology, 7:30 a.m. to 4:15 p.m., Sunday, July 28. Poster #89745
- "The Digital Clock and Recall Can Predict Functional Impairment
in Individuals with and Without Cognitive Impairment and Triage
Those in Need of Further Assessment," by Marissa Ciesla, PhD, senior clinical development
specialist, Linus Health. Virtual only.
- "Feasibility of Linus Health's Life-and-Health Questionnaire in
Primary Care Settings," by Ciesla. Virtual only.
- "The Digital Clock and Recall Is More Equitable and Less Biased
than the Mini-Mental State Examination in Terms of Ethnicity," by
Claudio Toro-Serey, PhD, senior data
scientist, Linus Health. Part of Basic Science and Pathogenesis:
Human Neuropathology, 7:30 a.m. to 4:15
p.m., Sunday, July 28. Poster
#89963
- "Digitizing the Trails-Making Test for Automatic Detection of
Cognitive Impairment: Validity and Reliability," by Toro-Serey.
Part of Basic Science and Pathogenesis: Human Neuropathology,
7:30 a.m. to 4:15 p.m., Sunday, July 28. Poster #89997
- "A Brief Digital Neuropsychological Protocol – I: Using
Artificial Intelligence-Assisted Technology to Assess Process and
Errors," by David Libon, PhD,
departments of Geriatrics, Gerontology, and Psychology, School of
Osteopathic Medicine, New Jersey Institute for Successful Aging,
Rowan University. Part of Biomarkers,
7:30 a.m. to 4:15 p.m., Sunday, July 28. Poster #91441
- "A Brief Digital Neuropsychological Protocol – II: Using
Artificial Intelligence to Assess Verbal Serial List Learning
Recognition Latency," by Libon. Part of Biomarkers, 7:30 a.m. to 4:15 p.m., Sunday, July 28. Poster #91489
- "A Brief Digital Neuropsychological Protocol – III: Using
Artificial Intelligence to Measure Semantic Memory with the 'Animal
Fluency' Test," by Libon. Part of Biomarkers, 7:30 a.m. to 4:15 p.m., Monday, July 29. Poster #91512
- "A Brief Digital Neuropsychological Protocol – IV: Relations
Compared to Comprehensive Paper and Pencil Neuropsychological
Assessment," by Ileana De
Anda-Duran, MD, Tulane University
School of Public Health and Tropical Medicine. Part of
Developing Topics: Clinical Manifestations, 8 a.m. to 4:15 p.m., Wednesday, July 31. Poster #95672
For more details about Linus Health's research, click here.
Those attending AAIC are invited to visit the Linus Health team at
booth #830 during the show. For more information about Linus
Health, connect with us here.
About Linus Health
Linus Health is a Boston-based digital health company focused on
transforming brain health for people across the world. By advancing
how we detect and address cognitive and brain disorders –
leveraging cutting-edge neuroscience, clinical expertise, and
artificial intelligence – our goal is to enable a future where
people can live longer, happier, and healthier lives with better
brain health. Linus Health's digital cognitive assessment platform
delivers a proven, practical means of enabling early detection;
empowers providers with actionable clinical insights; and supports
individuals with personalized action plans. We are proud to partner
with leading healthcare delivery organizations, research
institutions, and life sciences companies to accelerate more
proactive intervention and personalized care in brain health. To
learn more about our practical solutions for proactive brain
health®, visit www.linushealth.com or follow us on
LinkedIn.
Media Contact:
Tara
Stultz
Amendola Communications for Linus Health
tstultz@acmarketingpr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/aaic-2024-linus-health-to-unveil-groundbreaking-research-at-leading-alzheimers-conference-302204929.html
SOURCE Linus Health